Trial site
Universita' Degli Studi G. D'annunzio Di Chieti
Chieti, 66100, ItalyNot linked to an institution yet
- 9running trials
- 14closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 23 trials
- Phase 43 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Completed14 trials
- Active, not recruiting6 trials
- Recruiting2 trials
- Not yet recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche3 trials
- Anthos Therapeutics, Inc.2 trials
- Eli Lilly and Company2 trials
- MoonLake Immunotherapeutics AG2 trials
- AbbVie1 trial
- and 13 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
NCT06587451· Phase 3· H e x a l AG· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511360-87-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Completed
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
NCT06176352· Phase 3· Hoffmann-La Roche· Source
Completed
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
NCT05901831· Phase 3· Bayer· Source
Completed
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· Phase 2· Prinnovation GmbH· Source
Completed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540· Phase 3· Novo Nordisk A/S· Source
Completed
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580· Phase 4· AbbVie· Source
Completed
Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study
2024-517183-31-00· Phase 2· Centro Di Riferimento Oncologico Di Aviano· Source
Terminated
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source
Terminated
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT03915964· Phase 4· Eli Lilly and Company· Source
Active, not recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· Phase 3· pharmaand GmbH· Source
Report an error